KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Abbott Laboratories (ABT) EBT Margin (2016 - 2025)

Abbott Laboratories' EBT Margin history spans 17 years, with the latest figure at 20.58% for Q4 2025.

  • For Q4 2025, EBT Margin rose 208.0% year-over-year to 20.58%; the TTM value through Dec 2025 reached 19.1%, up 238.0%, while the annual FY2025 figure was 19.1%, 238.0% up from the prior year.
  • EBT Margin for Q4 2025 was 20.58% at Abbott Laboratories, up from 19.17% in the prior quarter.
  • Across five years, EBT Margin topped out at 24.18% in Q1 2022 and bottomed at 13.08% in Q4 2022.
  • The 5-year median for EBT Margin is 17.88% (2023), against an average of 18.01%.
  • The largest annual shift saw EBT Margin soared 1135bps in 2021 before it crashed -815bps in 2023.
  • A 5-year view of EBT Margin shows it stood at 20.29% in 2021, then crashed by -36bps to 13.08% in 2022, then skyrocketed by 34bps to 17.53% in 2023, then grew by 6bps to 18.5% in 2024, then rose by 11bps to 20.58% in 2025.
  • Per Business Quant, the three most recent readings for ABT's EBT Margin are 20.58% (Q4 2025), 19.17% (Q3 2025), and 19.3% (Q2 2025).